Seres Therapeutics (NASDAQ:MCRB) reported quarterly losses of $(2.08) per share which missed the analyst consensus estimate of $(1.88) by 10.64 percent. This is a 155.47 percent decrease over earnings of $3.75 per share from the same period last year. The company reported $358.000 thousand in sales this quarter.